Our research division accelerates breakthrough medicines through AI-driven discovery, precision genomics, and a global network of clinical trials spanning 28 countries.
Targeted research streams engineered to address unmet medical needs across complex disease states.
CRISPR-Cas9 delivery systems, CAR-T optimization, and in vivo gene editing for hereditary and acquired disorders.
Targeting Alzheimer's, Parkinson's, and ALS through neuroinflammation modulation and protein aggregation inhibitors.
Next-gen checkpoint inhibitors, tumor microenvironment reprogramming, and personalized neoantigen vaccines.
Targeted small molecules and enzyme replacement therapies for ultra-rare genetic conditions with <1% prevalence.
Real-time tracking of our lead candidates across all phases of clinical development.
| Candidate | Indication | Mechanism | Phase | Expected Milestone |
|---|---|---|---|---|
| AZP-4912 | Non-Small Cell Lung Cancer | PD-L1/CD47 Bispecific | Phase III | 2026 H2 Data Readout |
| AZP-8821 | Early-Onset Alzheimer's | Anti-Tau Microtubule Stabilizer | Phase IIb | 2027 H1 Pivotal |
| AZP-1105 | Sickle Cell Disease | In Vivo CRISPR Editing | Phase I | 2026 Q4 Dose Escalation |
| AZP-6634 | Generalized Anxiety Disorder | 5-HT2A Partial Agonist | Preclinical | 2027 Q2 IND Submission |
| AZP-0092 | Hepatitis C (HCV) | Pan-Genotypic NS5A Inhibitor | FDA Approved | Commercial Launch |
State-of-the-art laboratories and clinical sites operating 24/7 across key innovation corridors.
We believe breakthroughs happen through shared knowledge. Zenth Pharma publishes peer-reviewed data, open-sources non-proprietary tools, and partners with 140+ academic institutions worldwide.
Whether you're an academic researcher, biotech partner, or clinical site looking to collaborate, our open innovation team is ready to connect.